Pharmaceuticals News

Pharmaceuticals

Eli Lilly targets infectious disease prevention through acquisitions of Curevo, LimmaTech, and Vaccine Company

Eli Lilly and Company has announced separate agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. The multi-firm transactions pivot the pharmaceutical manufacturer toward specialized vaccine technology platforms.

2 days ago • United States

Pharmaceuticals

Anupam Rasayan accelerates downstream integration through major equity acquisition in Bliss GVS Pharma

Specialty chemicals producer Anupam Rasayan India has structured a deal to purchase up to a 43.3% interest in Bliss GVS Pharma for INR 13,695.1 million, followed by a public tender offer for another 26%. The move bridges chemical supply with finished drug manufacturing.

2 days ago • India

Pharmaceuticals

Zydus Lifesciences expands US oncology footprint with 166.4 million USD acquisition of Assertio Holdings

Zydus Lifesciences has entered a definitive agreement to acquire US-based Assertio Holdings for approximately $166.4 million. The all-cash transaction secures a specialized commercial platform in oncology supportive care, aligning with Zydus’s strategy to build a durable, high-margin specialty business in the North American market.

2 days ago • India;United States

AI & Automation

Owkin to build biopharma AI Agents for Astrazeneca under three-year k pro licensing deal

Owkin has signed a three-year licensing agreement with AstraZeneca to develop biopharma AI agents on its K Pro platform, integrating multimodal data and agentic AI into AstraZeneca’s decision workflows for competitive intelligence, reducing manual analysis.

2 days ago • France;United States

Mergers & Acquisitions

Bayer executes 2.45 billion USD acquisition of Perfuse Therapeutics to target ocular ischemia

Bayer has agreed to acquire biopharmaceutical firm Perfuse Therapeutics for up to $2.45 billion. The deal secures full rights to PER-001, a Phase II clinical asset designed to treat Glaucoma and Diabetic Retinopathy by addressing underlying ischemia rather than traditional pressure-lowering methods.

2 days ago • Germany;United States

Pharmaceuticals

Alcami acquires Tjoapack to expand CDMO footprint in US and Europe

Alcami Corporation has completed the acquisition of Tjoapack, a contract packaging organisation with facilities in the US and the Netherlands. The combined entity employs over 1,400 personnel across more than 1 million square feet, supporting 80 commercial products and adding QP release services in Europe.

2 days ago • Europe;United States

Pharmaceuticals

Merck completes $53 per share acquisition of Terns Pharmaceuticals, adding CML drug

Merck has completed its acquisition of Terns Pharmaceuticals through a cash tender offer at $53 per share, representing approximately 86% of outstanding shares. TERN-701, granted FDA Breakthrough Therapy Designation for chronic myeloid leukemia, will be advanced by Merck, with the transaction expected to result in a $5.8 billion R&D expense charge.

2 days ago • United States

Mergers & Acquisitions

Sun Pharma to acquire Organon in $11.75bn all-cash outbound deal

Sun Pharmaceutical Industries has signed a definitive agreement to acquire US-based Organon & Co for $11.75 billion in an all-cash transaction, marking one of the largest outbound deals by an Indian drugmaker, with closing expected in early 2027.

2 days ago • India;United States

Mergers & Acquisitions

Lilly to Acquire Ajax Therapeutics in deal worth up to $2.3bn

Eli Lilly has agreed to acquire Ajax Therapeutics for up to $2.3 billion, gaining AJ1-11095, a Phase 1 first-in-class Type II JAK2 inhibitor for myelofibrosis patients who have failed or become resistant to existing Type I JAK2 therapies.

2 days ago • United States

Investments & Funding

GHIT Fund invests $8.5 million in five Global R&D Projects for malaria and NTD drugs

The GHIT Fund has committed JPY 1.37 billion (USD 8.5 million) to five R&D projects targeting malaria and neglected tropical diseases, including preclinical antimalarial development and multi-country trials for eumycetoma treatment fosravuconazole.

2 days ago • India;Japan;Kenya;Senegal;United States

Mergers & Acquisitions

UCB expands into regenerative medicine with 1.15 billion USD acquisition of Neurona Therapeutics

Biopharmaceutical leader UCB has agreed to acquire Neurona Therapeutics for an initial 650 million USD to secure a pioneering cell therapy platform. The deal integrates NRTX-1001, a stem cell-based treatment for drug-resistant epilepsy, into UCB’s portfolio, signaling a shift from symptomatic management to functional neural repair.

2 days ago • Belgium;United States

Pharmaceuticals

Traws Pharma secures $10 million PIPE with $50 million warrant upside for flu trial

Traws Pharma has entered into a securities purchase agreement for a PIPE financing expected to provide $10 million in gross proceeds, with up to $50 million additional from milestone-based warrants. The funding will support the company's influenza programme through a human challenge trial in the UK following MHRA approval.

2 days ago • United Kingdom

Investments & Funding

World Bank approves $500 million Morocco loan for jobs and green growth reforms

The World Bank has approved a $500 million financing package for Morocco under its First Jobs and Green Growth Development Policy Loan. The programme supports labour market reforms, SME development, clean energy investment, and pharmaceutical export expansion, with targets including 330,000 job seekers and over 40,000 new childcare places.

2 days ago • Morocco

Pharmaceuticals

Shionogi secures up to $482 million BARDA contract for Fetroja antibiotic production in US

Shionogi Inc. has been awarded a BARDA Project BioShield contract initially funded at $119 million, with options up to $482 million, to establish US manufacturing for antibiotic Fetroja and expand its use against biothreat pathogens including plague and melioidosis.

2 days ago • Japan;United States